Ultra fast-acting insulin lispro biosimilar (Perosphere)

Ultra fast-acting insulin lispro生物类似药 (Perosphere)

Report date: 2022/07/04 19:38:02

Base Information

Drug NameUltra fast-acting insulin lispro biosimilar (Perosphere)
Drug Alias NameUltra rapid-acting insulin lisproUltra fast-acting insulin lispro生物仿制药 (Perosphere)URAL
ClassificationBiologics > BiosimilarBiologics > Protein drugs > Recombinant protein > Recombinant hormone
Mechanisms of ActionInsulin receptor agonists
TargetsInsulin receptor
Therapy Area/IndicationsDiabetes Mellitus, Type 1
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryGermany
CombinationsNo
Global Highest StatusDiscontinued (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesPerosphere Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesPerosphere Pharmaceuticals Inc
Active IndicationsN/A
Inactive IndicationsDiabetes Mellitus, Type 1

Other Information

ATC CodeN/A
Related LinksN/A